Tech Company Financing Transactions
EdiGene Funding Round
On 4/11/2019, EdiGene announced $15 million in Series B financing from CareNet, Fast Track Initiative and Mizuho Capital of Japan.
Transaction Overview
Company Name
Announced On
4/11/2019
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series B
Investors
Proceeds Purpose
EdiGENE plans to use the proceeds of the financing to advance the groundbreaking science forward, extend its leadership position in gene modulation technology, and progress pipeline programs towards the clinic where they will impact patients suffering from serious genetic diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 1st St. Riverview II 18th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
EdiGene is a world leading genome editing company founded in 2015. The mission of EdiGene is to translate the cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer, and into creative solutions to advance drug discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dong Wei
Chief Operating Officer
David Si
Chief Technical Officer
Pengfei Yuan
Founder
Wensheng Wei
VP - R & D
Riguo Fang
Browse more venture capital transactions:
Prev: 4/11/2019: Extend venture capital transaction
Next: 4/11/2019: Scout Bio venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs